FIBCD1 Activators
FIBCD1 activators delineate into two prominent classes based on their modus operandi. The first class, which includes compounds such as EGF, Chlorpromazine, and Dynasore, function by influencing other endocytic pathways that operate alongside FIBCD1. For example, Chlorpromazine and Dynasore obstruct clathrin-mediated endocytosis, resulting in an increased reliance on FIBCD1 for endocytic processes. This obstruction enhances the endocytic role of FIBCD1 by making other pathways less competitive. Genistein follows a similar logic; by suppressing caveolin-dependent endocytosis, it amplifies FIBCD1's role in this cellular process.
The second class of activators, including Phorbol 12-myristate, Wortmannin, and Latrunculin A, act more directly on the biochemical pathways that involve FIBCD1. Phorbol 12-myristate, for instance, activates PKC, thereby involving lipid-raft mediated endocytosis, a mechanism where FIBCD1 can also participate. Latrunculin A and Cytochalasin D disrupt actin polymerization and, by doing so, stress the importance of FIBCD1's endocytic pathways that are independent of actin. By affecting these pathways, the compounds can enhance the endocytic functions governed by FIBCD1.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $60.00 $108.00 | 21 | |
Blocks clathrin-mediated endocytosis. By inhibiting this pathway, FIBCD1-mediated endocytosis becomes more prominent. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynamin inhibitor that disrupts vesicle formation in clathrin-mediated endocytosis, accentuating the role of FIBCD1 in endocytosis. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates PKC which is involved in lipid-raft mediated endocytosis, potentially supporting FIBCD1 function in this form of endocytosis. | ||||||
Dansylcadaverine | 10121-91-2 | sc-214851 sc-214851A sc-214851B | 100 mg 250 mg 1 g | $51.00 $87.00 $235.00 | 4 | |
Clathrin-mediated endocytosis inhibitor; its inhibitory action may enhance the role of FIBCD1 in other forms of endocytosis. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Tyrosine kinase inhibitor that can suppress caveolin-dependent endocytosis, thereby emphasizing FIBCD1's role in endocytosis. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor that impacts macropinocytosis, potentially making FIBCD1-mediated endocytosis more salient. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Disrupts actin polymerization, which is necessary for some forms of endocytosis, therefore increasing reliance on FIBCD1's endocytic mechanisms. | ||||||
Filipin III | 480-49-9 | sc-205323 sc-205323A | 500 µg 1 mg | $116.00 $145.00 | 26 | |
Disrupts lipid rafts, which can modulate the functional capability of FIBCD1 in lipid-raft mediated endocytosis. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Inhibits actin polymerization and therefore affects forms of endocytosis that require actin, increasing the relative importance of FIBCD1. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $215.00 $622.00 | 5 | |
Ras farnesyltransferase inhibitor that can impact endocytic processes, indirectly augmenting the functional role of FIBCD1. | ||||||